STAT

Before a biotech stock debacle, one Republican congressman made a prescient trade

Rep. John Culberson made a prescient sale to avoid losses when a tiny biotech's stock tanked. The stock was a favorite of several GOP representatives.
Rep. John Culberson made a prescient sale to avoid losses when a tiny biotech company's stock tanked.

A biotech stock meltdown last week led to huge paper losses for several congressional Republicans who had bought into the tiny company. But one politician-turned-investor was spared. Turns out, he had sold his shares just two weeks before news of a negative clinical trial decimated the company’s value.

Rep. John Culberson of Houston was among a half dozen House Republicans to invest in Innate Immunotherapeutics,

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Abortion Pill Arguments, A Merck Drug Approval, And More
U.S. Supreme Court justices focused on plaintiffs' right to sue the FDA to reinstate restrictions on a commonly used abortion pill, suggesting they are unlikely to restrict access.
STAT1 min read
STAT+: New Gene Therapy, To Be Priced At $4.25 Million, Has Already Transformed Children’s Lives
The world's most expensive treatment offers a near-cure for young children and redemption for its developer, but steep challenges still loom.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CAR-T Drugs For Myeloma, CVS Rebate Credits, And More
A FDA panel voted in favor of expanding use of CAR-T therapy in multiple myeloma, despite concerns about side effects.

Related Books & Audiobooks